Stock TNFA TNF PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

TNF Pharmaceuticals, Inc. Stock

Equities

TNFA

US62856X2018

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 02:11:46 2025-01-13 pm EST 		5-day change 1st Jan Change
1.405 USD +11.07% Intraday chart for TNF Pharmaceuticals, Inc. +20.09% +22.17%
Dec. 19 TNF Pharmaceuticals, Inc. Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by Glp-1 Weight Loss Drugs CI
Nov. 14 TNF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI

Valuation: TNF Pharmaceuticals, Inc.

Capitalization 3.17M 3.1M 2.91M 2.6M 4.57M 273M 5.16M 35.6M 13.21M 112M 11.88M 11.64M 500M P/E ratio 2022
-2.94x
P/E ratio 2023 -1.46x
Enterprise value -1.71M -1.67M -1.57M -1.4M -2.46M -147M -2.78M -19.17M -7.11M -60.42M -6.4M -6.27M -269M EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
94.88%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data

Chart: TNF Pharmaceuticals, Inc.

Dynamic Chart

Latest news: TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by Glp-1 Weight Loss Drugs Dec. 19 CI
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
TNF Pharmaceuticals Secures Strategic Investment From Prevail Partners; Shares Rise 24-10-02 MT
TNF Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Prevail Partners 24-09-30 CI
Top Premarket Decliners 24-09-26 MT
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline 24-08-21 CI
TNF Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 24-08-19 CI
MyMD Pharmaceuticals, Inc. will Change its Ticker to TNFA from MYMD 24-07-24 CI
MyMD Pharmaceuticals Rebrands to TNF Pharmaceuticals; Trading Under New Symbol to Begin Wednesday 24-07-22 MT
MyMD Pharmaceuticals, Inc. has Changed its Name to TNF Pharmaceuticals, Inc 24-07-22 CI
MyMD Pharmaceuticals, Inc. Announces Management Changes 24-06-17 CI
TNF Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. 24-06-16 CI
TNF Pharmaceuticals, Inc. amended terms of the transaction 24-05-22 CI
More news

Press Releases: TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs Dec. 19 BU
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference Dec. 09 BU
TNF Pharmaceuticals : Announces Strategic Equity Investment Priced at a Premium to Market Form 8 K 24-10-07 PU
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market 24-10-02 BU
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline 24-08-21 BU
More press releases

Quotes and Performance

1 day+11.46%
1 week+17.10%
Current month+19.14%
1 month+19.14%
3 months-14.91%
6 months-24.30%
Current year+19.14%
More quotes

Course Extremes

1 week
1.12
Extreme 1.12
1.48
1 month
1.07
Extreme 1.0669
1.58
Current year
1.11
Extreme 1.11
1.48
1 year
1.05
Extreme 1.05
6.30
3 years
1.05
Extreme 1.05
184.50
5 years
1.05
Extreme 1.05
298.50
10 years
1.05
Extreme 1.05
298.50
More quotes

Managers and Directors: TNF Pharmaceuticals, Inc.

Director TitleAgeSince
Mitchell Glass PSD
 President 74 2024-06-13
Ian Rhodes DFI
 Director of Finance/CFO 52 2021-04-14
Robert Schatz IRC
 Investor Relations Contact - -
Manager TitleAgeSince
Joshua Silverman CHM
 Chairman 56 -
Bill White BRD
 Director/Board Member 65 2017-08-07
Craig Eagle BRD
 Director/Board Member 58 2021-04-15
More insiders

ETFs: TNF Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
VANGUARD US TOTAL MARKET SHARES INDEX ETF ETF Vanguard US Total Market Shares Index ETF
0.00% 293,477 M€ -0.57% -
More ETFs: TNF Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
TNF PHARMACEUTICALS, INC. Stock TNF Pharmaceuticals, Inc.
+11.46%+17.10%-77.50%-99.03%3.49M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.54%+0.33%-7.70%+78.22%105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-2.12%-4.97%-27.38%+10.48%74.98B
ARGENX SE Stock argenx SE
-1.68%+4.00%+82.18%+149.31%39.79B
BIONTECH SE Stock BioNTech SE
-4.99%-1.88%+18.46%-41.89%29.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-0.36%+1.53%-25.97%-54.52%20.86B
BEIGENE, LTD. Stock BeiGene, Ltd.
+1.63%-2.31%+1.86%-25.28%18.83B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-0.56%+2.71%+5.99%+77.44%14.27B
GENMAB A/S Stock Genmab A/S
-2.49%+0.10%-24.31%-31.42%14B
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-1.79%+1.03%+410.12%+647.88%13.16B
Average -0.24%+1.81%+35.57%+71.12% 33.08B
Weighted average by Cap. -1.74%+0.81%+16.88%+64.45%
See all sector performances

Financials

2022 2023
Net sales - -
Net income -15.2M -14.85M -13.94M -12.46M -21.94M -1.31B -24.74M -171M -63.35M -538M -57.01M -55.82M -2.4B -4M -3.91M -3.67M -3.28M -5.77M -345M -6.51M -44.94M -16.67M -142M -15M -14.69M -631M
Net Debt -4.69M -4.59M -4.31M -3.85M -6.78M -404M -7.64M -52.74M -19.57M -166M -17.61M -17.24M -741M -4.87M -4.76M -4.47M -4M -7.04M -420M -7.93M -54.77M -20.32M -173M -18.28M -17.9M -769M
More financial data * Estimated data

Company Profile

Logo TNF Pharmaceuticals, Inc.
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
Employees
6
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
25-01-13 1.405 $ +11.07% 361,032
25-01-10 1.265 $ -1.17% 110,324
25-01-08 1.280 $ +7.56% 241,762
25-01-07 1.190 $ +1.71% 37,433
25-01-06 1.170 $ -1.68% 67,176

Delayed Quote Nasdaq, January 13, 2025 at 10:16 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart TNF-PHARMACEUTICALS-INC More financial data
  1. Stock Market
  2. Equities
  3. TNFA Stock